Omalizumab as Add‐on Therapy in a Patient With Severe Asthma and OSA

Respirology Case Reports - United Kingdom
doi 10.1002/rcr2.518
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma

Prescriber
Pharmacology
2017English

ABS37: Add-On Omalizumab Improves Asthma Control Across Multiple Measures of Response in Patients With Severe Persistent Allergic (IgE-mediated) Asthma

Primary Care Respiratory Journal
2006English

Omalizumab in Patients With Severe Asthma and Persistent Sputum Eosinophilia

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

A Phase III Randomized Controlled Trial of Tiotropium Add-On Therapy in Children With Severe Symptomatic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2017English

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

PRS44 Cost Utility Analysis of Omalizumab Therapy for Severe Asthma Patients in Thailand

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

First Experience With Omalizumab in a Child With Severe Persistent Asthma in Turkey: Case Report

Turkiye Klinikleri Journal of Medical Sciences
Medicine
2010English

Efficacy and Tolerability of Atorvastatin as Add on Therapy in the Treatment of Chronic Stable (Moderate-Severe) Asthma for a Duration of 8 Weeks

International Journal of Basic & Clinical Pharmacology
2013English

A Review of Omalizumab for the Management of Severe Asthma

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy